Last reviewed · How we verify
SB206 12%
SB206 is a nitric oxide-releasing topical agent that delivers nitric oxide to skin lesions to promote healing and reduce bacterial burden.
SB206 is a nitric oxide-releasing topical agent that delivers nitric oxide to skin lesions to promote healing and reduce bacterial burden. Used for Molluscum contagiosum, Warts.
At a glance
| Generic name | SB206 12% |
|---|---|
| Also known as | berdazimer sodium, NVN1000 |
| Sponsor | Novan, Inc. |
| Drug class | Nitric oxide-releasing topical agent |
| Target | Nitric oxide pathway |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
SB206 is a proprietary formulation that releases nitric oxide, a signaling molecule with antimicrobial and wound-healing properties. Nitric oxide has been shown to have broad-spectrum antimicrobial activity and can enhance tissue repair processes. The 12% formulation is designed for topical application to treat dermatological conditions.
Approved indications
- Molluscum contagiosum
- Warts
Common side effects
- Application site irritation
- Erythema
- Pruritus
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum (PHASE2)
- A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC (PHASE3)
- A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (PHASE3)
- A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |